Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma

31 July 2020: Clinical Research

Ying Yang ^AEF , Zhuogang Liu ^ABC , Hongtao Wang ^ACEG*

DOI: 10.12659/MSM.923716

Med Sci Monit 2020; 26:e923716

Table 1 The relationship between ALC and prognostic factors (P<0.05).

Characteristics	Low ALC groupALC <1.43×109/L	High ALC groupALC ≥1.43×109/L	P-value
Sex			0.297
Male	36	31
Female	15	20
Age, y			0.003
	17	32
≥60	34	19
BMI, kg/m			0.992
	20	22
≥22.85	21	23
DS staging			0.13
Stage I	1	6
Stage II	7	8
Stage III	43	37
Group A	31	43	0.008
Group B	20	8
ISS staging			0.007
Stage I	1	4
Stage II	12	24
Stage III	38	23
ISS dichotomy			0.002
Early stage	13	28
Late stage	38	23
L-ISS staging
Stage I	0	5
Stage II	12	44
Stage III	39	2
L-ISS dichotomy
Early stage	12	49
Late stage	39	2
M-fraction type			0.644
IgG	24	25
IgA	8	12
Light chain	14	12
Light chain type			0.231
κ	24	31
lambda;	24	19
HGB, g/L
	44	27
≥100	7	24
PLT			0.038
	23	13
≥135×10/L	28	38
LDH, U/L			0.971
	29	31
≥243	20	22
β2-MG, mg/L			0.004
	11	25
≥5.5	37	24
ALB, g/L			0.19
	35	29
≥35	16	22
Ca, mmol/L			0.065
	48	42
≥2.75	3	9
IgG dichotomy, g/L			0.26
	17	14
≥70	6	10
IgA dichotomy, g/L			0.848
	5	8
≥50	3	4